Lupin receives final approval for generic generic Drospirenone, Ethinyl Estradiol, Levomefolate Calcium Tablets and Levomefolate Calcium Tablets
Drug maker Lupin today said it has received approval from the US health regulator to market Drospirenone, Ethinyl Estradiol, Levomefolate Calcium tablets, used to prevent pregnancy, in the American market.
The company has received final approval from the United States Food and Drug Administration (FDA) to market its product which is a generic version of Bayer HealthCare Pharmaceutical Inc's Beyaz tablets, Lupin said in a statement.
The product is indicated for use by women to prevent pregnancy and treat symptoms of premenstrual dysphoric disorder (PMDD).
According to IQVIA MAT April 2018 data, Drospirenone, Ethinyl Estradiol, Levomefolate Calcium Tablets and Levomefolate Calcium Tablets, 3 mg/0.02 mg/0.451 mg and 0.451 mg had annual sales of around USD 82.2 million in the US.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)